Aflibercept in the treatment of metastatic colorectal cancer

Tzu Fei Wang, Albert Craig Lockhart

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesistargeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical development of aflibercept.

Original languageEnglish (US)
Pages (from-to)19-30
Number of pages12
JournalClinical Medicine Insights: Oncology
StatePublished - Jan 4 2012
Externally publishedYes


  • Aflibercept
  • Angiogenesis
  • Colorectal cancer
  • Targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Aflibercept in the treatment of metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this